论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Chen P, Xu W, Luo Y, Zhang Y, He Y, Yang S, Yuan Z
Received 28 July 2016
Accepted for publication 12 December 2016
Published 6 March 2017 Volume 2017:10 Pages 1423—1431
DOI https://doi.org/10.2147/OTT.S118366
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 6
Editor who approved publication: Dr Jianmin Xu
Background: Breast cancer affects millions of people with a high mortality rate
throughout the world; microRNA 543 (miR-543) has been reported to suppress
progression in some kinds of cancers, but has not been reported in breast
cancer. Thus, the purpose of this study is to investigate the function of
miR-543 in breast cancer cells.
Methods: Two cell lines, MCF-7 and MDA-MB-231, were selected to
be the research objects; the miR-543 overexpression and knockdown models were
established in the study by transforming miR-543 mimics and miR-543 inhibitor.
Real-time polymerase chain reaction,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Western blot,
clone formation and cell flow cytometer assay were used to test the miR-543’s function.
Dual-luciferase assay was used for the detection of miR-543 and ERK2 targeting
relationship.
Results: The results showed that the cell proliferation and
cell cycle were inhibited, and the capability of cell apoptosis was upregulated
when miR-543 was overexpressed; we found that there was a target relationship
between ERK2 and miR-543. Furthermore, downstream factors of mitogen-activated
protein kinase (MAPK)/extracellular signal-regulated kinase-2 (ERK2) pathway,
including RSK2 and MSK1, were decreased in miR-543 overexpression model.
Conclusion: This study provides series evidences to support that
breast cancer progression was inhibited by miR-543 via direct targeting of ERK2
in MAPK/ERK signal pathway, which may provide a molecular basis for better
treatment for patients.
Keywords: microRNA 543, breast cancer, ERK2,
apoptosis, cell cycle, proliferation